Start of generic AXERT tabletsNovo Nordisk announces FDA authorization of Tresiba for diabetes treatment BioCryst also received created notification from the Section of Health insurance and Human Services by means of a Stop-Work Purchase directing the business to cease focus on peramivir under its U.S. Government contract, aside from certain activities primarily linked to the forthcoming FDA Type C achieving which is planned. The notification verified that the Biomedical Advanced Study and Advancement Authority will continue steadily to support and fund particular activities that are essential to accomplish immediate milestones, in addition to activities deemed necessary to maintain compliance with FDA rules or even to fulfill pending FDA requests., a clinical-stage biopharmaceutical firm focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it provides entered into a termination agreement with AstraZeneca , such that all the privileges to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product applicant, tenapanor, are returned to Ardelyx. Ardelyx has agreed to pay AstraZeneca $15 million upfront and also other future contingent obligations. Concurrently, Ardelyx can pay yet another $10 million in R&D costs and for the acceleration of the transfer of the program back again to Ardelyx. Ardelyx formed a partnership with AstraZeneca in October 2012 to develop and commercialize Ardelyx's discovered portfolio of NHE3 inhibitors including tenapanor internally.